Addex initiates Ph IIa trial of ADX10061
Geneva, Switzerland-based Addex Pharmaceuticals has initiated a proof-of-concept study on its drug candidate ADX10061 for smoking cessation, the second compound from its portfolio to enter Phase II clinical trials within the past year.
The multicenter, double-blind, Phase IIa study is being carried out at specialist smoking cessation centers in the USA. Smokers will receive ADX10061 or placebo for a seven-week period together with a targeted smoking cessation counselling program. Efficacy measures include the proportion of smokers continuously abstinent for a four-week period, total number of weeks of smoking abstinence, measures of nicotine craving and withdrawal, as well as mood scores.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze